Anthera Pharma (ANTH) Initiates Phase 2b for Lupus Treament Candidate A-623
Tweet Send to a Friend
Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH) today announced it has initiated PEARL-SC, the Phase 2b study of A-623, a novel inhibitor ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
